| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Hibifolin is a novel and potent flavonol glycoside derived from herbal plants, it possessed a strong protective activity against cell death induced by aggregated Aβ. Application of hibifolin in primary cortical neurons prevented the Aβ-induced cell death in a dose-dependent manner. In cultured cortical neurons, the pre-treatment of hibifolin abolished Aβ-induced Ca2+ mobilization, and also reduced Aβ-induced caspase-3 and caspase-7 activation. Moreover, DNA fragmentation induced by Aβ could be suppressed by hibifolin. In addition to such protection mechanisms, hibifolin was able to induce Akt phosphorylation in cortical neurons, which could be another explanation for the neuroprotection activity. These results therefore provided the first evidence that hibifolin protected neurons against Aβ-induced apoptosis and stimulated Akt activation, which would be useful in developing potential drugs or food supplements for treating AD.
| References | |
|---|---|
| Additional Infomation |
Hibifolin has been reported in Sedum album, Helicteres isora, and Abelmoschus manihot with data available.
|
| Molecular Formula |
C21H18O14
|
|---|---|
| Molecular Weight |
494.3592
|
| Exact Mass |
494.07
|
| CAS # |
55366-56-8
|
| PubChem CID |
5490334
|
| Appearance |
White to yellow solid powder
|
| LogP |
0.3
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
35
|
| Complexity |
861
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C1=CC(=C(C=C1C2=C(C(=O)C3=C(O2)C(=C(C=C3O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)O)O)O
|
| InChi Key |
KHVMAMXQPVHXTJ-ORYXKJSJSA-N
|
| InChi Code |
InChI=1S/C21H18O14/c22-6-2-1-5(3-7(6)23)16-13(28)11(26)10-8(24)4-9(25)17(18(10)33-16)34-21-15(30)12(27)14(29)19(35-21)20(31)32/h1-4,12,14-15,19,21-25,27-30H,(H,31,32)/t12-,14-,15+,19-,21+/m0/s1
|
| Chemical Name |
beta-D-Glucopyranosiduronic acid, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4-oxo-4H-1-benzopyran-8-yl
|
| Synonyms |
Gossypetin 8-O-beta-D-glucuronide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~202.28 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (5.06 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (5.06 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0228 mL | 10.1141 mL | 20.2282 mL | |
| 5 mM | 0.4046 mL | 2.0228 mL | 4.0456 mL | |
| 10 mM | 0.2023 mL | 1.0114 mL | 2.0228 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Fig. 1.Hibifolin prevents Aβ-induced cell toxicity.Neuroscience Letters, Volume 461, Issue 2, 11 September 2009, Pages 172-176. |
Fig. 2.Pre-treatment of hibifolin prevents intracellular Ca2+mobilization induced by Aβ.Neuroscience Letters, Volume 461, Issue 2, 11 September 2009, Pages 172-176. |
Fig. 4.Activation of Akt signaling pathway by hibifolin in cortical neurons. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
